ArticlePsycho-oncology2026
The Role of Metacognition, Intolerance of Uncertainty, and Cognitive-Attentional Syndrome in Differentiating Fear of Cancer Recurrence.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesThis study tested (1) whether intolerance of uncertainty (IU) and negative metacognitive beliefs independently differentiate fear of cancer recurrence (FCR) status, and (2) whether mediation by cognitive-attentional syndrome (CAS) elements modify the relationships of IU and metacognitive beliefs with FCR status.
methodsBaseline data from 384 participants (collected ∼15.6 months post-diagnosis) pooled from a prospective longitudinal study and an FCR intervention trial were analyzed. Measures included FCRI-SF (FCR), MCQ-30 (metacognitive beliefs), IUS-12 (IU), and CAS-1 (CAS). FCR status was classified based on the FCRI-SF scores as non-clinical (< 13), subclinical (13-21), and clinically significant (≥ 22). Fully adjusted multinomial logistic regression examined direct effects of IU and metacognitive domains on FCR status and indirect effects via CAS.
resultsCompared to the non-clinical group (n = 116), subclinical (n = 190) and clinically-significant (n = 78) FCR groups showed greater negative beliefs about worry (OR range 1.297-1.500, p < 0.001), higher IU (OR 1.050-1.066, p = 0.037), increased use of CAS metacognitive strategies (OR 1.077-1.108, p = 0.021-< 0.001), and less perceived need to control thoughts (OR 0.847-0.857, p = 0.003-0.027). Clinically-significant FCR was additionally associated with poorer cognitive confidence (OR 1.122, p = 0.030). CAS partially mediated associations of FCR status with negative beliefs about worry, cognitive confidence, and IU, and fully mediated the association with need to control thoughts.
conclusionsIU and negative metacognitive beliefs can characterize individuals vulnerable to differentially-elevated FCR. CAS centrally mediates the relationships between FCR, IU, and metacognition. Cognitive-behavioral interventions for FCR explicitly targeting CAS should disrupt the impact of IU and metacognitive beliefs on FCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.